Literature DB >> 16470786

Crossroads in GDNF therapy for Parkinson's disease.

Todd B Sherer1, Brian K Fiske, Clive N Svendsen, Anthony E Lang, J William Langston.   

Abstract

The development of a neuroprotective or neuroregenerative therapy for Parkinson's disease (PD) would be a major therapeutic advance. Unfortunately, results from a recent controlled clinical study delivering the neurotrophic factor, glial-derived neurotrophic factor (GDNF), directly into brain did not demonstrate efficacy and safety of such a treatment. A critical review of available data suggests that there are questions that need to be answered before the future of GDNF as a therapy for PD can be determined. Copyright (c) 2006 Movement Disorder Society.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16470786     DOI： 10.1002/mds.20861

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


  48 in total

1.  Effects of GDF5 overexpression on embryonic rat dopaminergic neurones in vitro and in vivo.

Authors:  David B O'Sullivan; Patrick T Harrison; Aideen M Sullivan
Journal:  J Neural Transm (Vienna)       Date:  2010-03-27       Impact factor: 3.575

2.  Pericyte-derived glial cell line-derived neurotrophic factor increase the expression of claudin-5 in the blood-brain barrier and the blood-nerve barrier.

Authors:  Fumitaka Shimizu; Yasuteru Sano; Kazuyuki Saito; Masa-aki Abe; Toshihiko Maeda; Hiroyo Haruki; Takashi Kanda
Journal:  Neurochem Res       Date:  2011-10-16       Impact factor: 3.996

3.  AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth.

Authors:  Sang Ryong Kim; Tatyana Kareva; Olga Yarygina; Nikolai Kholodilov; Robert E Burke
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

Review 4.  Motor neuron trophic factors: therapeutic use in ALS?

Authors:  Thomas W Gould; Ronald W Oppenheim
Journal:  Brain Res Rev       Date:  2010-10-21

5.  Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF.

Authors:  M E Emborg; J Moirano; J Raschke; V Bondarenko; R Zufferey; S Peng; A D Ebert; V Joers; B Roitberg; J E Holden; J Koprich; J Lipton; J H Kordower; P Aebischer
Journal:  Neurobiol Dis       Date:  2009-08-04       Impact factor: 5.996

Review 6.  Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.

Authors:  Sha Mi; R Blake Pepinsky; Diego Cadavid
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 7.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons.

Authors:  J D Elsworth; D E Redmond; C Leranth; K B Bjugstad; J R Sladek; T J Collier; S B Foti; R J Samulski; K P Vives; R H Roth
Journal:  Exp Neurol       Date:  2008-02-15       Impact factor: 5.330

9.  Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.

Authors:  X Yue; D J Hariri; B Caballero; S Zhang; M J Bartlett; O Kaut; D W Mount; U Wüllner; S J Sherman; T Falk
Journal:  Neuroscience       Date:  2013-11-27       Impact factor: 3.590

10.  Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease.

Authors:  Stina Friling; Maria Bergsland; Susanna Kjellander
Journal:  BMC Neurosci       Date:  2009-12-11       Impact factor: 3.288
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.